Literature DB >> 10493517

Taxol affects nuclear lamina and pore complex organization and inhibits import of karyophilic proteins into the cell nucleus.

P A Theodoropoulos1, H Polioudaki, O Kostaki, S P Derdas, V Georgoulias, C Dargemont, S D Georgatos.   

Abstract

Treatment of human carcinoma cells with Taxol induces focal unraveling of the nuclear lamina and extensive clustering or ectopic localization of the nuclear pore complexes. These striking aberrations develop when the cells are transferred to drug-free medium and are allowed to complete mitosis. As could be confirmed by terminal deoxynucleotidyl transferase-mediated nick end labeling assays, 4,6-diamidino-2-phenylindole staining, 5-bromo-2-deoxyuridine incorporation, and examination of the nuclear lamins by Western blotting, the malformation of the nuclear envelope is not a consequence of apoptosis or G1 arrest. In fact, Taxol-treated cells possessing a defective nuclear envelope remain alive and replication-competent for at least 24 h, undergoing programmed death 72 h after removal of the drug. While still in the nonapoptotic state, these cells lose the ability to import karyophilic proteins into the nucleus. Diminished nucleocytoplasmic transport through the nuclear pore complex can be readily demonstrated by in vitro assays involving digitonin-permeabilized cells or in vivo monitoring of nuclear factor-kappaB translocation upon stimulation with tumor necrosis factor-alpha. These observations reveal novel cellular targets of antimicrotubule drugs and may pave the way for improved schemes of anticancer treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10493517

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Microtubule-interacting drugs induce moderate and reversible damage to human bone marrow mesenchymal stem cells.

Authors:  H Polioudaki; M-C Kastrinaki; H A Papadaki; P A Theodoropoulos
Journal:  Cell Prolif       Date:  2009-05-22       Impact factor: 6.831

2.  Nuclear Lamin A/C Expression Is a Key Determinant of Paclitaxel Sensitivity.

Authors:  Elizabeth R Smith; Justin Leal; Celina Amaya; Bing Li; Xiang-Xi Xu
Journal:  Mol Cell Biol       Date:  2021-06-23       Impact factor: 4.272

3.  AFM-detected apoptotic changes in morphology and biophysical property caused by paclitaxel in Ishikawa and HeLa cells.

Authors:  Kyung Sook Kim; Chang Hoon Cho; Eun Kuk Park; Min-Hyung Jung; Kyung-Sik Yoon; Hun-Kuk Park
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

4.  Centrosome maturation requires YB-1 to regulate dynamic instability of microtubules for nucleus reassembly.

Authors:  Atsushi Kawaguchi; Masamitsu N Asaka; Ken Matsumoto; Kyosuke Nagata
Journal:  Sci Rep       Date:  2015-03-05       Impact factor: 4.379

5.  High-throughput, microscope-based sorting to dissect cellular heterogeneity.

Authors:  Nicholas Hasle; Anthony Cooke; Sanjay Srivatsan; Heather Huang; Jason J Stephany; Zachary Krieger; Dana Jackson; Weiliang Tang; Sriram Pendyala; Raymond J Monnat; Cole Trapnell; Emily M Hatch; Douglas M Fowler
Journal:  Mol Syst Biol       Date:  2020-06       Impact factor: 11.429

6.  Drug-Triggered Self-Assembly of Linear Polymer into Nanoparticles for Simultaneous Delivery of Hydrophobic and Hydrophilic Drugs in Breast Cancer Cells.

Authors:  Sandeep Palvai; Libi Anandi; Sujit Sarkar; Meera Augustus; Sudip Roy; Mayurika Lahiri; Sudipta Basu
Journal:  ACS Omega       Date:  2017-12-07

Review 7.  Rationale for combination of paclitaxel and CDK4/6 inhibitor in ovarian cancer therapy - non-mitotic mechanisms of paclitaxel.

Authors:  Elizabeth R Smith; Marilyn Huang; Matthew P Schlumbrecht; Sophia H L George; Xiang-Xi Xu
Journal:  Front Oncol       Date:  2022-09-15       Impact factor: 5.738

8.  Cytoskeletal influences on nuclear shape in granulocytic HL-60 cells.

Authors:  Ada L Olins; Donald E Olins
Journal:  BMC Cell Biol       Date:  2004-08-19       Impact factor: 4.241

9.  Breaking malignant nuclei as a non-mitotic mechanism of taxol/paclitaxel.

Authors:  Elizabeth R Smith; Xiang-Xi Xu
Journal:  J Cancer Biol       Date:  2021
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.